Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
TSH Biopharm Corporation Limited (8432.TWO)
TWD50.20
+0.00 (+0.00%)
TW TWO Healthcare Drug Manufacturers - Specialty & Generic
Address
No. 3-1, Park Street 11503
Taipei, TW
Taipei, TW
CEO
Sze-Yuan Yang
Website
tshbiopharm.com
IPO
2012-04-30
ISIN TW0008432006
Description
TSH Biopharm Corporation Limited, a subsidiary of TTY Biopharm Company Limited, specializes in the development and commercialization of pharmaceutical products. Established in 1999 with its headquarters in Taipei, Taiwan, the company's market reach extends across Taiwan and other Asian territories. Its product portfolio encompasses a variety of therapeutic solutions, including treatments for cardiovascular, central nervous system, and gastrointestinal conditions, among others.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
TWD50.20
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
47.3K
Beta
0.32
Float Shares
15.12M
Free Float %
39.4%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.12% | -1.78% | -1.97% | -11.07% | -6.04% | -14.87% | -2.16% | +10.91% | +21.32% | -44.23% | -14.57% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
50.20
DCF (Unlevered)
83.25
+65.8%
DCF (Levered)
306.33
+510.2%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
7.08
Safe zone
Piotroski F-Score
8 / 9
Strong
MOAT Score
5 / 10
Developing
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
5 / 5
High
D/E Score
3 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%+19.8% ★ Q1'26: -0.5% (vs Q1'25)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+23.5% ★ Q1'26: +27.8% (vs Q1'25)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+12.8% Q1'26: +58.1% (vs Q1'25)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+16.3% ★ Q1'26: +18.5% (vs Q1'25)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+21.5% ★ Q1'26: +22.8% (vs Q1'25)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%+34.3% Q1'26: -0.1% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×0.12× ★ Q1'26: 0.11× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
Dec 2029 1 Rev. Ana. 1 EPS Ana. |
Dec 2030 1 Rev. Ana. 1 EPS Ana. |
Dec 2031 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
579.00M
est.
|
547.55M
est.
|
660.71M
est.
|
648.00M
est.
|
507.67M
est: 510.00M (-0.5%)
|
447.86M
est: 520.00M (-13.9%)
|
1.12B
est: 1.03B (+8.3%)
|
1.34B
est: 1.30B (+2.8%)
|
1.46B
1.46B – 1.46B
+12.0% YoY
|
648.00M
648.00M – 648.00M
-55.5% YoY
|
510.00M
510.00M – 510.00M
-21.3% YoY
|
520.00M
520.00M – 520.00M
+2.0% YoY
|
1.03B
1.03B – 1.03B
+98.1% YoY
|
1.30B
1.30B – 1.30B
+26.2% YoY
|
| EBITDA |
93.82M
est.
|
88.73M
est.
|
107.07M
est.
|
105.01M
est.
|
65.81M
est: 82.64M (-20.4%)
|
86.81M
est: 84.26M (+3.0%)
|
202.84M
est: 160.64M (+26.3%)
|
218.37M
est: 202.75M (+7.7%)
|
227.08M
227.08M – 227.08M
+12.0% YoY
|
101.06M
101.06M – 101.06M
-55.5% YoY
|
79.54M
79.54M – 79.54M
-21.3% YoY
|
81.10M
81.10M – 81.10M
+2.0% YoY
|
160.64M
160.64M – 160.64M
+98.1% YoY
|
202.75M
202.75M – 202.75M
+26.2% YoY
|
| EBIT |
79.00M
est.
|
74.71M
est.
|
90.15M
est.
|
88.41M
est.
|
56.20M
est: 69.58M (-19.2%)
|
77.26M
est: 70.95M (+8.9%)
|
173.89M
est: 138.70M (+25.4%)
|
218.37M
est: 175.06M (+24.7%)
|
196.06M
196.06M – 196.06M
+12.0% YoY
|
87.26M
87.26M – 87.26M
-55.5% YoY
|
68.68M
68.68M – 68.68M
-21.3% YoY
|
70.02M
70.02M – 70.02M
+2.0% YoY
|
138.70M
138.70M – 138.70M
+98.1% YoY
|
175.06M
175.06M – 175.06M
+26.2% YoY
|
| Net Income |
77.82M
est.
|
121.73M
est.
|
134.83M
est.
|
118.27M
est.
|
85.33M
est: 88.60M (-3.7%)
|
61.57M
est: 67.42M (-8.7%)
|
113.09M
est: 157.81M (-28.3%)
|
187.82M
est: 176.43M (+6.5%)
|
208.51M
208.51M – 208.51M
+18.2% YoY
|
158.84M
158.84M – 158.84M
-23.8% YoY
|
119.00M
119.00M – 119.00M
-25.1% YoY
|
90.55M
90.55M – 90.55M
-23.9% YoY
|
157.81M
157.81M – 157.81M
+74.3% YoY
|
176.43M
176.43M – 176.43M
+11.8% YoY
|
| SGA |
224.18M
est.
|
212.00M
est.
|
255.81M
est.
|
250.89M
est.
|
197.13M
est: 197.46M (-0.2%)
|
182.31M
est: 201.33M (-9.4%)
|
384.16M
est: 314.94M (+22.0%)
|
—
est: 397.49M (-100.0%)
|
445.19M
445.19M – 445.19M
+12.0% YoY
|
198.13M
198.13M – 198.13M
-55.5% YoY
|
155.94M
155.94M – 155.94M
-21.3% YoY
|
159.00M
159.00M – 159.00M
+2.0% YoY
|
314.94M
314.94M – 314.94M
+98.1% YoY
|
397.49M
397.49M – 397.49M
+26.2% YoY
|
| EPS |
2.02
est.
|
3.16
est.
|
3.50
est.
|
3.07
est.
|
2.22
est: 2.30 (-3.5%)
|
1.60
est: 1.75 (-8.6%)
|
2.94
est: 3.05 (-3.6%)
|
3.63
est: 3.41 (+6.5%)
|
4.03
4.03 – 4.03
+18.2% YoY
|
3.07
3.07 – 3.07
-23.8% YoY
|
2.30
2.30 – 2.30
-25.1% YoY
|
1.75
1.75 – 1.75
-23.9% YoY
|
3.05
3.05 – 3.05
+74.3% YoY
|
3.41
3.41 – 3.41
+11.8% YoY
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-12 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-11 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-08 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-07 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-06 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-05 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-05-04 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-30 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 2/5 | 3/5 |
| 2026-04-29 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-28 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-27 | A | 4/5 | 5/5 | 4/5 | 5/5 | 3/5 | 3/5 | 3/5 |
| 2026-04-24 | A | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 3/5 | 3/5 |
| 2026-04-23 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-22 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-21 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-20 | A- | 4/5 | 5/5 | 4/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-17 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
| 2026-04-16 | A- | 4/5 | 5/5 | 3/5 | 5/5 | 2/5 | 2/5 | 3/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
149.65M
OE per share TTM
3.42
Owner's Yield
4.81%
Maintenance CapEx ratio
4.81%
Maint CapEx / Avg PPE
4.6%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
No insider activity available.
Insider buys vs sells (history)
Insider history not available.
Recent insider transactions
No recent insider transactions.
Executive team
Top executives
EBIT / Employee
2.73M
Shares Outstanding
38.40M
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Sze-Yuan Yang | President | 7M | female |
| Chen-Ju Kan | Senior Manager of the Accounting Department | — | female |
| Chuan-Hsu Chen | Senior Director of Marketing | — | male |
| Hsin-Young Liu | Company Secretary | — | male |
| Jung-Liang Kao | Senior Division Director of Finance Division & Chief Financial Officer | — | male |
| Yu-Chung Wu | Senior Director of Sales | — | male |
ESG Score History
No data available for this company.
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 8432.TWO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
